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Abstract 
The effects of Nigella Sativa (NS) on plasma lipid concentrations are controversial. A systematic 
review and meta-analysis of randomized controlled trials (RCTs) was conducted to obtain a 
conclusive result in humans. 
PubMed-Medline, SCOPUS, Web of Science, and Google Scholar databases were searched (up to 
August 2015) to identify RCTs investigating the impact of NS on total cholesterol, LDL-cholesterol 
(LDL-C), HDL-cholesterol (HDL-C), and triglycerides concentrations. A random-effects model and 
the generic inverse variance weighting method were used for quantitative data synthesis. Meta-
regression, sensitivity analysis, and publication bias assessments were performed using standard 
methods. 
A total of 17 RCTs examining the effects of NS on plasma lipid concentrations were included. Meta-
analysis suggested a significant association between NS supplementation and a reduction in total 
cholesterol (weighed-mean-difference [WMD]: -15.65 mg/dL, 95% CI: -24.67, -6.63, p =0.001), 
LDL-C (WMD: -14.10 mg/dL, 95% CI: -19.32, -8.88, p <0.001), and triglyceride levels (WMD: -
20.64 mg/dL, 95% CI: -30.29, -11.00, p <0.001). No significant effect on HDL-C concentrations 
(WMD: 0.28 mg/dL, 95% CI: -1.96, 2.53, p =0.804) was found. A greater effect of NS seed oil 
versus seed powder was observed on serum total cholesterol and LDL-C levels, and an increase in 
HDL-C levels was found only after NS seed powder supplementation. 
NS has a significant impact on plasma lipid concentrations, leading to lower total cholesterol, LDL-
C, and TG levels while increased HDL-C is associated with NS powder only. Further RCTs are 
needed to explore the NS benefits on cardiovascular outcomes. 
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1. Introduction 
Nigella Sativa (NS), popularly known as black seed or black cumin, is an annual plant of the 
Ranunculaceae family which grows widely in many Middle Eastern countries and Southwest Asia. 
The seeds of NS are claimed to play antibacterial [1, 2], anti-inflammatory [3], immune-potentiating 
[4], antioxidant [5, 6], hypoglycemic [7, 8], antihypertensive [9], anti-obesity [10], bronchodilatory 
[11], neuro- and cardio-protective [12, 13], and antidiarrhoic effects [14], Increasing evidence also 
supports hypolipidemic properties of NS [13, 15-18]. The NS seeds contain many bioactive 
constituents, such as antioxidant compounds (mainly represented by thymoquinone and 
dithymoquinone), flavonoids, sterols, and polyunsaturated fatty acids [15], and the lipid-lowering 
effect is likely mediated by a synergistic action of its different components. Different mechanisms 
have been postulated, such as activation of the peroxisome proliferator-activated receptor gamma 
(PPAR-gamma) [19], increasing uptake of low-density lipoprotein cholesterol (LDL-C) by up-
regulation of hepatic LDL receptors [20], de novo suppression of cholesterol synthesis [20], 
reduction in dietary cholesterol absorption, and prevention of lipid peroxidation [6], 
There is growing interest in finding safe natural alternatives to common drugs used to treat 
dyslipidemia, one of the most important risk factor for cardiovascular diseases, particularly in 
patients resistant to or intolerant of statins [21]. Therefore, the lipid-lowering action of NS has been 
evaluated both in different experimental models, varying from normal [22] to dyslipidemic [23, 24], 
dysmetabolic [25], and diabetic animals [26], and in clinical studies, performed in healthy [27], 
dyslipidemic [28], dysmetabolic [29], and diabetic subjects [30]. Supplementation with NS has been 
associated with decreased concentrations of serum total cholesterol [23, 24, 26-29, 31-45], 
triglycerides [2, 23, 24, 26, 28, 31, 32, 34-41, 43, 44, 46], and/or increased concentrations of high-
density lipoprotein cholesterol (HDL-C) [23, 25, 28, 32, 34-36, 39, 41-44]. 
With respect to clinical findings, although some randomized controlled trials (RCTs) have been 
performed, the reported results have been controversial [9, 47-62]. Because of the variable duration 
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of studies, preparation of NS employed, study designs, and recruited populations, it is difficult to 
draw definitive conclusions on the hypolipidemic activity of this natural supplement. The aim of this 
study was therefore to perform a systematic review of RCTs and conduct a meta-analysis to evaluate 
the effect of NS supplementation on plasma lipid concentrations. 
 
2. Methods 
2.1 Search Strategy 
This study was designed according to the guidelines of the 2009 preferred reporting items for 
systematic reviews and meta-analysis (PRISMA) statement [63]. PubMed-Medline, SCOPUS, Web 
of Science, and Google Scholar databases were searched using the following search terms in titles 
and abstracts: (“Nigella sativa” OR “black seed” OR “black cumin” OR thymoquinone) AND 
(placebo) AND (hyperlipidemia OR hyperlipidaemia OR hyperlipidemic OR hyperlipidaemic OR 
hypolipidemic OR hypolipidaemic OR dyslipidemia OR dyslipidaemia OR dyslipidemic OR 
dyslipidaemic OR hypercholesterolemia OR hypercholesterolaemia OR hypercholesterolemic OR 
hypercholesterolaemic OR hypocholesterolemic OR hypocholesterolaemic OR "low-density 
lipoprotein" OR "high-density lipoprotein" OR cholesterol OR triglycerides OR hypertriglyceridemia 
OR hypertriglyceridaemia OR hypotriglyceridemic OR hypotriglyceridaemic OR LDL OR LDL-C 
OR LDL-cholesterol OR HDL- OR HDL-C OR HDL-cholesterol). The wild-card term ‘‘*’’ was 
used to increase the sensitivity of the search strategy. No language restriction was applied. The 
literature was searched from inception to August 18th, 2015.  
 
2.2 Study Selection 
The following criteria were used to identify eligible studies: (i) randomized placebo-controlled trials 
with either case-control or case-cross-over design, (ii) investigation of the effects of NS or 
thymoquinone on plasma/serum lipid concentrations, (iii) providing sufficient information on 
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baseline and end-trial plasma/serum lipid concentrations in both NS and control groups. Exclusion 
criteria were (i) experimental studies, (ii) observational studies, (iii) uncontrolled studies, and (iv) 
lack of sufficient information on baseline or end-trial lipid concentrations. In case of the latter item, 
authors of the article(s) were contacted and requested to provide necessary numerical data. 
 
2.3 Data extraction  
Eligible studies were reviewed, and the following data were abstracted: 1) first author's name; 2) year 
of publication; 3) country were the study was performed; 4) study design; 5) number of participants 
in the NS and control groups; 6) type and dose of NS supplement; 7) treatment duration; 9) age, 
gender, and body mass index (BMI) of study participants; and 9) data regarding baseline and follow-
up plasma concentrations of total cholesterol, LDL-C, HDL-C, and triglycerides. 
 
2.4 Quality assessment 
A systematic assessment of bias in the included studies was performed using the Cochrane criteria 
[64]. The items used for the assessment of each study were as follows: adequacy of sequence 
generation, allocation concealment, blinding, addressing of dropouts (incomplete outcome data), 
selective outcome reporting, and other potential sources of bias. According to the recommendations 
of the Cochrane Handbook, a judgment of “yes” indicated low risk of bias, while “no” indicated high 
risk of bias. Labeling an item as “unclear” indicated an unclear or unknown risk of bias. 
 
2.5 Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) 
[65]. Net changes in measurements (change scores) were calculated as follows: measure at end of 
follow-up − measure at baseline. For single-arm cross-over trials, net change in plasma 
concentrations of lipid indices were calculated by subtracting the value after control intervention 
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from that reported after treatment. All values were collated to mg/dL. Standard deviations (SDs) of 
the mean difference were calculated using the following formula: SD = square root [(SDpre-treatment)2 + 
(SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. If 
the outcome measures were reported in median and range (or 95% confidence interval [CI]), mean 
and standard SD values were estimated using the method described by Wan et al [66]. When only the 
standard error of the mean (SEM) was reported, standard deviation (SD) was estimated using the 
following formula: SD = SEM × sqrt (n), where n is the number of subjects. In order to avoid unit-
of-analysis error due to double-counting of subjects in the trials with more than 1 treatment arm, the 
control group was evenly (where possible) divided. 
Net changes in measurements (change scores) were calculated for parallel and cross-over trials, as 
follows: (measure at the end of follow-up in the treatment group − measure at baseline in the 
treatment group) − (measure at the end of follow-up in the control group − measure at baseline in the 
control group). A random-effects model (using DerSimonian-Laird method) and the generic inverse 
variance method were used to compensate for the heterogeneity of studies in terms of study design, 
treatment duration, and the characteristics of populations being studied [67]. Effect sizes were 
expressed as weighted mean difference (WMD) and 95% confidence interval (CI). Inter-study 
heterogeneity was assessed using Cochran Q test and I2 index. In order to evaluate the influence of 
each study on the overall effect size, sensitivity analysis was conducted using leave-one-out method, 
i.e. iteratively removing one study each time and repeating the analysis [68-70]. 
 
2.6 Meta-regression 
A weighted random-effects meta-regression using unrestricted maximum likelihood model was 
performed to assess the association between the overall estimate of effect size and potential 
moderator variables including dose and duration of NS supplementation. 
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2.7 Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot asymmetry, 
Egger’s weighted regression, and “fail safe N” tests. Duval & Tweedie “trim and fill” method was 
used to adjust the analysis for the effects of publication bias [71]. 
 
3. Results 
3.1 Flow of studies 
After multiple database searches, 52 published studies were identified, and the abstracts reviewed. 
Twenty-five did not meet the inclusion criteria and were excluded. Next, 22 full text articles were 
careful assessed and reviewed; of which 5 studies were excluded for not measuring plasma lipid 
concentrations (n=3), incomplete lipid data (n=1), and non-original article (n=1). Finally, 17 studies 
were eligible and included in the systematic review and meta-analysis. The study selection process is 
shown in Figure 1. 
 
3.2 Characteristics of included studies 
Data were pooled from 17 RCTs that included 1185 subjects, with 616 in the NS arm and 569 in the 
control arm. Included studies were published between 2008 and 2015. The clinical trials used 
different forms and doses of NS. Three studies investigated NS powder 1 g/day [49, 56, 57], two 
studies investigated NS powder 1.5 g/day [47, 50], one study investigated NS powder 1.6 g/day [58], 
three studies investigated NS powder 2 g/day [51, 61, 62], two studies investigated NS powder 2 
spoons/day [52, 60], two studies investigated NS oil 5 ml/day [48, 55], one study investigated NS oil 
100 mg/day [9], one study investigated NS oil 200 mg/day [9], one study investigated NS oil 1 g/day 
[53], and two studies investigated NS oil 3 g/day [54, 59]. The range of intervention periods was 
from 4 weeks [52, 62] up to 3 months [50, 54, 55, 58]. The most of included studies were parallel-
group design [9, 47-57, 59-62], only one study was cross-over design [58]. Selected trials enrolled 
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subjects with metabolic syndrome [47, 56], overweight [51], obesity [50, 59], mild hypertension [9], 
hyperlipidemia [51, 52, 60-62], type 2 diabetes [53-55], menopausal women [56-58], and healthy 
subjects [48, 49] (Table 1). 
 
3.3 Risk of bias assessment 
Several of the included studies were characterized by lack of information about the allocation 
concealment and blinding of participants, personnel, and outcome assessors. Some trials did not 
provide sufficient information of sequence generation [9, 48, 50, 52, 53, 57, 60]. In addition, some 
trials had other biases related with the study design, such as open-label single arm [58] and single 
blind [52, 60]. However, most of evaluated studies showed low risk of bias according to incomplete 
outcome data and selective outcome reporting. Details of the quality of bias assessment are shown in 
Table 2. 
 
3.4 Effect of NS supplementation on plasma lipid concentrations 
Overall, the impact of NS supplementation on plasma concentrations of total cholesterol, LDL-C, 
HDL-C, and triglycerides was assessed in 15, 16, 16 and 18 treatment arms, respectively. NS 
supplementation was found to significantly reduce plasma concentrations of total cholesterol (WMD: 
-15.65 mg/dL, 95% CI: -24.67, -6.63, p = 0.001; Figure 2), LDL-C (WMD: -14.10 mg/dL, 95% CI: -
19.32, -8.88, p < 0.001; Figure 2), and triglycerides (WMD: -20.64 mg/dL, 95% CI: -30.29, -11.00, 
p < 0.001; Figure 2), while no significant effect on HDL-C concentrations (WMD: 0.28 mg/dL, 95% 
CI: -1.96, 2.53, p = 0.804; Figure 2) was found. All these effects were robust in the sensitivity 
analysis (Figure 3), and the overall estimate of effect size was not significantly driven by a single 
study. 
When the meta-analysis was stratified according to the type of NS supplement that was administered, 
a greater effect of NS seed oil versus seed powder was observed on serum total cholesterol and LDL-
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cholesterol concentrations, while the effect of both supplement types on plasma triglycerides levels 
was comparable (Figure 4). With respect to plasma HDL-C concentrations, a significant elevation 
was found in the subgroups of studies with NS seed powder, but not NS seed oil (Figure 4). 
 
3.5 Meta-regression 
Meta-regression analysis was conducted to evaluate the association between changes in plasma lipid 
concentrations and potential confounders including dose and duration of supplementation with NS. 
No significant association was found between changes in lipid parameters and duration of 
supplementation with NS (Figure 5). With respect to dose, there were significant associations with 
changes in plasma total cholesterol (slope: 0.001; 95% CI: 0.0002, 0.015; p = 0.044) and HDL-C 
concentrations (slope: 0.004; 95% CI: 0.003, 0.005; p < 0.001), but not with LDL-C and triglyceride 
levels (Figure 6). 
 
3.6 Publication bias 
Visual inspection of funnel plots suggested an asymmetry in the meta-analyses of NS’s effects on 
plasma lipid concentrations. Using “trim and fill” method, 2, 3 and 3 potentially missing studies were 
imputed for the meta-analyses of triglycerides, LDL-C, and HDL-C (Figure 7). Corrected effect 
sizes (following imputation of potentially missing studies) and the results of Egger’s linear 
regression, Begg’s rank correlation, and “fail safe N” tests are summarized in Table 3. 
 
4. Discussion 
The results of the present meta-analysis of RCTs showed that supplementation with NS significantly 
reduces plasma concentrations of total cholesterol, LDL-C, and triglycerides. This effect was greater 
with seed oil, while seed powder was found to be associated with a significant elevation in HDL-C 
levels. 
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The effects of NS seem to be predominant on LDL-C. The ethanol extract of NS is an agonist of the 
PPAR-gamma gene [19], whose activation appears to be associated with the enhanced expression of 
CD36 [72], a cellular scavenger receptor for atherogenic LDL, and ATP-binding cassette transporter 
A1, a reverse cholesterol transporter involved in the cholesterol efflux from macrophages [73]. 
Thymoquinone, an active ingredient of NS oil, can up-regulate hepatic LDL receptors [20], inhibit 3-
hydroxy-3-methylglutaryl-coenzyme A reductase gene [20], and down-regulate ApoB100 gene [74], 
thus leading to both increased clearance and reduced synthesis of LDL-C. NS could also stimulate 
bile acid excretion [75] and has a slight anorexic effect [76]. Moreover, many of phytochemicals 
present in the NS seeds may contribute to its hypocholesterolemic effects: β-sitosterol inhibits the 
intestinal absorption of dietary cholesterol [77, 78], anti-oxidants protect tissues from lipid 
peroxidation [6], and the rich content of unsaturated fatty acids may contribute to the reduction in 
and prevention of cholesterol oxidation [27]. 
Almost all previous experimental studies in animals [23, 24, 26, 31-44, 79-81], but one [25], showed 
a reduction in LDL-C after NS supplementation. Consistently, small clinical studies confirmed a 
significant LDL-C reduction after the consumption of NS in both healthy individuals [27] and 
dysmetabolic patients [28, 29, 45]. In our meta-analysis, seed oil showed a greater benefit on serum 
total cholesterol and LDL-C concentrations than seed powder. Owing to the different compositions 
and doses of NS preparations, along with the inter-study heterogeneities, it is difficult to justify this 
result with certainty. However, it has been demonstrated that, differently from the powder deriving 
from seed crushing, the preparation processes of the seed oil may lead to significant compositional 
changes in the active ingredients, with increased content of the thymoquinone, to which is attributed 
most of the biological activity of NS [82]. Controlled thermal processing of the seeds, responsible for 
thymoquinone accumulation at temperatures between 50 and 150°C, could explain the higher 
biological activity of the oil from heated seeds [82]. Furthermore, thymoquinone is soluble in fat, and 
the NS oil may be more effective than the aqueous extract form [59]. 
11  
We found a highly significant effect of NS supplementation in reducing triglyceride concentrations, 
in line with many animal and clinical studies [2, 23, 24, 26, 28, 31, 32, 34-41, 43, 44, 46, 83-85], but 
not all [24, 25, 29, 33, 40, 45]. Possible mechanisms responsible for the triglyceride-lowering effect 
of NS may be due to its components. The high content of polyunsaturated fats may affect both the 
synthesis and catabolism of triglyceride-rich lipoproteins through increasing PPAR-gamma and 
lipoprotein lipase activities [59]. Triglyceride-rich lipoproteins exert pro-atherogenic effects, 
commonly attributed to their remnant lipoprotein particles [86, 87]. Remnants are involved in the 
mechanisms of endothelial dysfunction and atherosclerosis progression, and appear to be an 
independent risk factor for cardiovascular disease [86, 87]. Furthermore, the nigellamines A-(5) have 
been shown to reduce triglyceride levels in vitro similarly to clofibrate [88]. 
Finally, the impact of NS on HDL-C is more controversial: no overall significant effect was found in 
this meta-analysis, and data from literature are contrasting. Experimental and clinical studies have 
reported positive effects [23, 25, 28, 32, 34-36, 39, 41-44, 81, 83, 85], but others did not confirm 
these findings [2, 24, 26, 29, 31, 33, 34, 37, 38, 40, 45]. 
The divergent results may be due to differences in dosage and type of NS supplementation, dietary 
habits, physical activity level, duration of the intervention, ethnicity, laboratory and clinical 
characteristics of the patients studied. Indeed, an HDL-C increase was reported in studies where 
participants were assigned to an exercise program [51, 60], in experimental studies where NS 
determined a relevant decrement of triglycerides and insulin resistance, thus resulting in a lower 
clearance of HDL [25, 36, 54], or in studies administering seed powder [52]. A possible explanation 
for the superiority of seed powder on HDL-C may be the higher content of seeds of unsaturated fatty 
acids, mainly linoleic and oleic acids [16]. Regardless of the impact of NS supplementation on 
plasma HDL-C levels, it is noteworthy that the concept of HDL-C elevation for protection against 
atherosclerotic cardiovascular disease has been assailed by some recent large-scale trials [89-91]. In 
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fact, it is currently uncertain if HDL-C elevation could be considered as a treatment target to reduce 
the risk of cardiovascular outcomes [92]. 
It could be hypothesized that a longer period of NS supplementation might be necessary in order to 
impact on HDL-C values. Indeed, the RCTs included in this meta-analysis are short-lasting 
(maximum 12 weeks), while significant improvements were observed in clinical studies with 6 
months supplementations [93]. 
A major point is that the value of a supplementation should be evaluated not only in term of 
surrogate endpoints, but also for its effects on morbidity and mortality. Many clinical studies have 
reported benefits of NS on fasting glucose, insulin resistance, and metabolic syndrome [30, 47, 50, 
53-56], body weight and central obesity [10, 29, 50, 55, 59], arterial pressure [9, 94], and 
inflammation [50]. Lastly, additional cardio-protective effects have been demonstrated in 
experimental studies: NS inhibits the plaque formation [95] and arachidonic acid-induced platelet 
aggregation [96], improves endothelial function [97], reduces intima/media ratio [95], induces 
bradycardia [98], ameliorates cardiac hemodynamics [99], exerts cardio-protection against 
exogenous and endogenous toxic products [13]. Long-term RCTs are surely needed to evaluate the 
impact of NS on cardiovascular outcomes. These preliminary results, however, report a wide range 
of benefits other than the hypolipidemic effects, suggesting a potential use of NS as an adjunct to 
statin therapy, in consideration of both the significant residual cardiovascular risk in statin-treated 
individuals and the limitation of statins in achieving optimal LDL-C concentrations. 
The safety of NS has been documented in clinical practice. Only a few adverse events have been 
reported in humans: two cases of contact dermatitis after topical use [100]. In addition to its pungent 
bitter taste, NS may cause mild, transient nausea and dyspepsia [47], exert a slight anorexic [76] and 
weight-loss effect [10, 29]. High doses of thymoquinone were found to induce hepatic oxidative 
stress in mice [101], but humans with solid tumors have tolerated a dose up to 2600 mg/day in a 
phase I clinical study, with no side effects [102]. NS seeds, particularly in the powdered form, 
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resulted in a potent hepato-protective effect in experimental models [6, 103], while a non-toxic 
increase in liver enzymes has been observed after NS oil administration in women [104]. In the 
included studies, there was no difference in the frequency of adverse effects between treated and 
placebo groups, and among all participants only one treated subject was reported to quit for nausea 
[47]. 
No significant association was found between changes in lipid parameters and duration of 
supplementation with NS in our meta-analysis. Ibrahim demonstrated that 1 month after cessation of 
supplementation, the lipid concentrations changed towards the pretreatment levels, thus suggesting 
the need of a life-long assumption [57]. On the other hand, in the available study with the longer 
follow-up (6 months), the effect of NS started after 4 days and continued for the entire follow-up 
[93]. 
A dose-dependent effect of NS was observed for changes in total cholesterol and HDL-C, but not for 
triglycerides and LDL-C. We showed in this meta-analysis that NS was more effective against 
triglyceride and LDL-C concentrations. It could be therefore hypothesized that any dosage was 
effective on these parameters, while higher doses of NS are needed to affect the other lipid variables, 
i.e. triglycerides and HDL-C. 
RCTs with larger cohorts and longer follow-up are however needed to ascertain the most effective 
duration and dosage of NS supplementation, that at present are not defined. 
 
4.1 Strengths and limitation 
To the best of authors’ knowledge, this is the first systematic review and meta-analysis of RTCs 
investigating the effect of NS on plasma lipid concentrations. However, a number of limitations 
should be mentioned. First of all, the heterogeneity of RCTs included in the meta-analysis have to be 
considered, as healthy individuals, patients with hypertension, type 2 diabetes, dyslipidemia, and 
metabolic syndrome were enrolled. Different preparations, doses, and durations of supplementation 
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were employed. Part of this inter-study heterogeneity was addressed by choosing a random-effects 
model for meta-analysis and performing subgroup and meta-regression analyses. Furthermore, some 
RCTs were not primarily designed to assess the effects of NS on lipid concentrations. Finally, the 
number of subjects studied in the present meta-analysis was relatively small, but the current pooled 
population size was sufficient to detect a significant lipid-lowering effect of NS. All observed effects 
in meta-analysis were robust in the sensitivity analysis, and the overall estimate of effect size was not 
significantly driven by a single study. 
 
5. Conclusions 
This present study provides for the first time a quantitative pooled estimate of the impact of NS 
supplementation on plasma lipid concentrations evaluated in RCTs, showing that NS significantly 
reduces plasma concentrations of total cholesterol, LDL-C, and triglycerides. These results are 
intriguing, considering the good safety profile and low cost of NS. Additional studies are required to 
define the optimal dosage and duration of this supplementation to obtain a favorable effect on lipid 
blood values. Finally, the value of adding NS supplements to conventional and novel LDL- [105-
108] and triglyceride-lowering therapies [86, 109, 110] remains to be investigated in future studies. 
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Table 1. Demographic characteristics of the included studies.  
Author Study design Target 
Population 
Treatment 
duration 
n Study groups Age, years Female 
(n, %) 
BMI, (kg/m2) Systolic blood 
pressure 
(mmHg) 
Diastolic 
blood 
pressure 
(mmHg) 
Total 
cholesterol 
(mg/dl) 
LDL 
cholesterol 
(mg/dl) 
HDL 
cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
Amin et al. 
(2015) 
Randomized,  
double-blind, 
placebo-
controlled 
Men with 
metabolic 
syndrome 
8 weeks  
62 
63 
 
NS powder 1.5 g/day 
Placebo 
 
45.1±11.7 
41.5±12.8 
 
0 (0.0) 
0 (0.0) 
 
27.4±3.1 
27.5±4.1 
 
131.8±20.2 
125.5±16.7 
 
82.5±12.1 
76.8±11.5 
 
184.3±33.6 
180.8±23.3 
 
110.2±28.0 
119.5±27.3 
 
34.3±7.8 
33.7±7.4 
 
169.5±44.3 
163.6±42.7 
Bin Sayeed 
et al. (2013) 
Randomized, 
double-blind, 
placebo-
controlled 
Healthy 
male 
volunteers 
9 weeks  
20 
20 
 
NS powder 1 g/day 
Placebo 
 
55.8±0.57 
55.9±0.65 
 
0 (0.0) 
0 (0.0) 
 
24.77±0.34 
24.55±0.18 
 
ND 
ND 
 
ND 
ND 
 
148.9±8.4 
151.2±5.3 
 
113.7±8.4 
112.1±13.8 
 
25.1±12.0 
29.0±12.0 
 
116.0±3.1 
114.3±2.2 
Datau et al. 
(2010) 
Randomized, 
double-blind, 
placebo-
controlled 
Men with 
central 
obesity 
3 months  
19 
20 
 
NS powder 1.5 g/day 
Placebo 
 
ND 
ND 
 
0 (0.0) 
0 (0.0) 
 
ND 
ND 
 
130.53±13.11 
123.50±12.68 
 
80.53±13.93 
80.0±7.96 
 
ND 
ND 
 
ND 
ND 
 
35.60±5.21 
39.14±7.65 
 
202.05±134.31 
115.05±81.06 
Dehkordi et 
al. (2008) 
Randomized, 
double-blind, 
placebo-
controlled 
Men with 
mild 
hypertension 
8 weeks  
36 
39 
33 
 
NS oil 100 mg/day 
NS oil 200 mg/day 
Placebo 
 
44.6±1.3 
43.7±1.3 
43.1±1.4 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
23.9±0.8 
24.1±0.8 
24.5±0.7 
 
151.2±1.3 
149.5±1.3 
148.2±1.2 
 
93.2±0.5 
95.1±0.8 
94.5±0.8 
 
201.2±9.1 
200.7±8.2 
189.7±8.7 
 
128.2±6.1 
127.7±6.8 
123.5±5.4 
 
51.8±3.4 
52.7±3.1 
47.2±2.9 
 
127.9±10.7 
118.0±9.7 
121.2±10.3 
Farzaneh et 
al. (2014) 
Randomized, 
double-blind, 
placebo-
controlled 
Overweight 
females with 
hypercholes-
terolemia 
8 weeks 8 
8 
NS powder 2 g/day 
Placebo 
34.14±10.54 
33.0±4.34 
8 (100.0) 
8 (100.0) 
25.39±0.75 
25.85±1.45 
ND 
ND 
ND 
ND 
221.5±31.34 
232.75±12.85 
119.1±11.96 
120.5±10.39 
45.62±10.02 
48.37±8.61 
167.88±18.61 
173.8±50.43 
Fatima et al. 
(2014) 
Single-blind, 
placebo-
controlled 
Hyper-
lipidemia 
4 weeks  
30 
30 
 
NS powder 2 spoons/day 
Placebo 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
31.7±3.11 
35.87±2.22 
 
ND 
ND 
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Heshmati et 
al. (2015) 
Randomized, 
double-blind, 
placebo-
controlled 
Type 2 
diabetes 
12 weeks  
36 
36 
 
NS oil 3 g/day 
Placebo 
 
45.3±6.5 
47.5±8.0 
 
54.3* 
51.4* 
 
29.5±4.4 
28.6±4.3 
 
ND 
ND 
 
ND 
ND 
 
216.8±51.7 
228.3±49.0 
 
132.9±48.0 
140.6±44.8 
 
38.2±5.3 
38.5±5.5 
 
228.0±74.4 
244.4±59.8 
Hosseini et 
al. (2013) 
Randomized, 
double-blind, 
placebo-
controlled 
Type 2 
diabetes 
3 months  
35 
35 
 
NS oil 5 ml/day 
Placebo 
 
48.74±7.33 
50.72±5.69 
 
21 (60.0) 
19 (54.2) 
 
30.81±3.55 
30.92±3.67 
 
ND 
ND 
 
ND 
ND 
 
250.0±30.0 
246.9±31.1 
 
171.8±27.0 
168.0±7.1 
 
47.7±9.2 
46.8±9.0 
 
182.5±62.3 
179.9±52.4 
Ibrahim et 
al. (2014)a 
Randomized, 
placebo-
controlled 
Menopausal 
women with 
metabolic 
syndrome 
2 months  
18 
17 
 
NS powder 1 g/day 
Placebo 
 
ND 
ND 
 
18 (100.0) 
17 (100.0) 
 
ND 
ND 
 
ND 
ND 
 
ND 
ND 
 
233.1±40.4 
234.2±40.7 
 
179.7±35.8 
186.7±23.1 
 
60.9±10.0 
52.5±10.9 
 
133.7±31.6 
132.6±42.8 
Ibrahim et 
al. (2014)b 
Randomized, 
placebo-
controlled 
Menopausal 
women 
2 months  
19 
18 
 
NS powder 1 g/day 
Placebo 
 
53.22±2.16 
53.71±3.57 
 
19 (100.0) 
18 (100.0) 
 
27.18±4.34 
27.75±4.38 
 
129.33±15.44 
138.40±18.90 
 
77.13±9.16 
83.93±15.73 
 
235.5±40.2 
234.3±39.4 
 
179.8±34.4 
177.5±18.6 
 
50.7±8.5 
51.0±9.7 
 
155.9±31.0 
152.3±46.9 
Latiff et al. 
(2014) 
Open label 
single arm, 
controlled 
Peri-
menopausal 
women 
12 weeks  
69 
69 
 
NS powder 1.6 g/day 
Placebo 
50.1±7.6  
69 (100.0) 
69 (100.0) 
 
26.31±4.89 
26.03±4.66 
 
122.32±15.25 
121.42±14.89 
 
79.07±7.76 
78.42±8.48 
 
225.1±47.2 
225.8±46.0 
 
165.9±204.216
6.3±198.0 
 
60.3±14.7 
58.8±17.4 
 
125.8±74.4 
124.9±70.0 
Mahdavi et 
al. (2015) 
Randomized, 
double-blind, 
placebo-
controlled 
Obese 
women 
8 weeks 43 
41 
NS oil 3 g/day 
Placebo 
41.5±11.7 
39.3±9.9 
43 (100.0) 
41 (100.0) 
32.4±1.5 
32.6±1.5 
120.5±10.3 
120.4±10.4 
7.7±0.7 
7.9±0.6 
203.1±42.2 
191.7±41.1 
129.1±32.3 
119.2±33.0 
48.8±11.6 
49.3±13.4 
130.2±65.9 
115.5±64.7 
Moeen-Ud-
Din et al. 
(2014) 
Single-blind, 
placebo-
controlled 
Hyper-
lipidemia 
6 weeks 27 
30 
NS powder 2 spoons/day 
Placebo 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
202.45±1.54 
189.15±3.90 
38.81±3.90 
36.11±2.11 
ND 
ND 
Qidwai et al. 
(2009) 
Randomized, 
double-blind, 
placebo-
controlled 
Hypercholes
-terolemia 
6 weeks 39 
34 
NS powder 2 g/day 
Placebo 
45.58±10.86 
46.86±11.00 
6 (10.0) 
8 (14.0) 
27.13±3.88 
28.26±6.75 
128.90±18.37 
122.30±17.76 
81.82±11.24 
80.45±11.48 
209.07±28.63 
217.11±27.72 
145.76±23.30 
144.43±24.0 
40.53±8.52 
41.74±10.63 
163.14±71.43 
157.12±84.53 
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Sabzghabaee 
et al. (2012) 
Randomized, 
placebo-
controlled 
Hypercholes
-terolemia 
4 weeks 37 
37 
NS powder 2 g/day 
Placebo 
40.38** 
38.4** 
17 (45.9) 
16 (43.2) 
25.01** 
23.19** 
ND 
ND 
ND 
  ND 
235.24±28.29 
233.39±26.24 
144.58±19.06 
138.36±19.05 
51.48±15.45 
48.03±8.70 
173.91±69.35 
173.88±47.92 
Hadi et al. 
(2015) 
Randomized, 
placebo-
controlled 
Type 2 
diabetes 
8 weeks 23 
20 
NS oil 1 g/day 
Placebo 
51.4±9.2 
56.0±3.4 
10 (43.5) 
10 (50.0) 
28.4±4.4 
28.8±8.1 
ND 
ND 
ND 
  ND 
189.0±48.2 
175.0±41.7 
114.0±38.2 
102.0±39.6 
48.1±7.5 
48.2±10.5 
156.0±73.9 
142±61.8 
Amini et al. 
(2013) 
Randomized, 
placebo-
controlled 
Healthy 
subjects with 
200 mg/dL< 
total 
cholesterol<
300 mg/dL 
8 weeks 35 
35 
NS oil 5 mL/day 
Placebo 
42.3±13.8 
36.3±13.6 
17 (48.5) 
18 (51.5) 
ND 
ND 
ND 
ND 
ND 
ND 
196.7±35.7 
184.2±28.2 
111.5±24.2 
112.4±18.1 
43.0±10.1 
42.4±6.4 
210.2±103.8 
191.6±6.4 
Values are expressed as mean ± SD 
*Percentage only 
Abbreviations: NS, Nigella sativa; ND, no data; BMI, body mass index. 
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Table 2. Risk of bias assessment of the included studies according to the Cochrane 
guidelines. 
 
 
Study 
Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants, 
personnel 
and outcome 
assessors 
Incomplete  
outcome 
data 
Selective 
outcome 
reporting 
Other 
sources 
of bias 
Amin et al. (2015) 
 
L L L L L L 
Bin Sayeed et al. (2013) 
 
L L L L L L 
Datau et al. (2010) 
 
U U U L L U 
Dehkordi et al. (2008) 
 
U U U L L U 
Farzaneh et al. (2014) 
 
L U U L L U 
Fatima et al. (2014) 
 
U U U H U U 
Heshmati et al. (2015) 
 
L L L L L L 
Hosseini et al. (2013) 
 
L U U L U U 
Ibrahim et al. (2014)a 
 
L U U U U U 
Ibrahim et al. (2014)b 
 
U U U L L U 
Latiff et al. (2014) 
 
H H H L L H 
Mahdavi et al. (2015) 
 
L L L L L L 
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Moeen-Ud-Din et al. (2014) 
 
U U U H U U 
Qidwai et al. (2009) 
 
L L L L L L 
Sabzghabaee et al. (2012) 
 
L U U L L U 
Hadi et al., (2015) 
 
U U L L H L 
Amini et al. (2013) 
 
U U L L L L 
L, low risk of bias; H, high risk of bias; U, unclear risk of bias. 
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Table 3. Assessment of publication bias in the meta-analysis of NS effects on plasma concentrations of lipids. 
 Corrected effect sizea Begg’s rank correlation test, Egger's linear regression test Fail safe N test 
WMD 95% CI Kendall’s Taua z-value p-value Intercept 95% CI p-value nb 
Total cholesterol - - 0.11 0.59 0.553 -0.32 -3.53, 2.89 0.834 432 
LDL-C -17.21 -22.66, -11.76 -0.06 0.32 0.753 -0.50 -2.54, 1.55 0.610 982 
HDL-C -0.63 -2.76, 1.50 -0.14 0.83 0.405 0.99 -1.68, 3.65 0.445 - 
Triglycerides -17.80 -27.10, -8.50 0.14 0.77 0.44 -2.04 -3.44, -0.65 0.007 347 
aWith continuity correction; bNumber of theoretically missing studies to bring the p-value to > 0.05. 
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FIGURE LEGENDS  
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis.   
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of NS supplementation on plasma lipid concentrations. 
Figure 3. Results of leave-one-out sensitivity analysis for the impact of NS supplementation 
on plasma lipid concentrations. 
Figure 4. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of NS supplementation on plasma lipid concentrations in the subgroups of trials 
studying the effects of NS powder and black seed oil. 
Figure 5. Random-effects meta-regression plots of the association between mean changes in 
plasma concentrations of lipids and NS dose. 
Figure 6. Random-effects meta-regression plots of the association between mean changes in 
plasma concentrations of lipids and duration of NS supplementation. 
Figure 7. Funnel plot displaying publication bias in the studies reporting the impact of NS 
supplementation on plasma lipid concentrations.  
